Which statement about COPD GOLD treatment indications is true?

Which statement about COPD GOLD treatment indications is true?

• A. LABA and LAMA are indicated for Category A
• B. SAMA or SABA is never used in COPD management
• C. Inhaled corticosteroids are never indicated
• D. Inhaled corticosteroids are indicated for Category C or worse

Answer: (D)

In COPD management, the treatment plan is guided by risk of exacerbations plus symptom burden. Inhaled corticosteroids are reserved for patients at higher risk of exacerbations, specifically those in the higher-risk groups (C or D), where ICS-containing regimens help reduce exacerbations and may be used with a long-acting bronchodilator. They are not used as monotherapy and are not typically indicated in the low-risk groups unless there are other features such as frequent exacerbations or asthma-COPD overlap. The other statements don’t fit this framework. Short-acting bronchodilators (SABA or SAMA) are commonly used as rescue, and can be part of initial management, so saying they’re never used isn’t accurate. Inhaled corticosteroids are not universally indicated for all COPD patients; they’re specifically considered for those in Category C or D due to higher exacerbation risk, not for everyone. And while LABA and LAMA are useful maintenance therapies, saying they’re indicated for Category A overstates their role, since Category A guidance centers on as-needed short-acting bronchodilators with minimal maintenance therapy.

In COPD management, the treatment plan is guided by risk of exacerbations plus symptom burden. Inhaled corticosteroids are reserved for patients at higher risk of exacerbations, specifically those in the higher-risk groups (C or D), where ICS-containing regimens help reduce exacerbations and may be used with a long-acting bronchodilator. They are not used as monotherapy and are not typically indicated in the low-risk groups unless there are other features such as frequent exacerbations or asthma-COPD overlap.

The other statements don’t fit this framework. Short-acting bronchodilators (SABA or SAMA) are commonly used as rescue, and can be part of initial management, so saying they’re never used isn’t accurate. Inhaled corticosteroids are not universally indicated for all COPD patients; they’re specifically considered for those in Category C or D due to higher exacerbation risk, not for everyone. And while LABA and LAMA are useful maintenance therapies, saying they’re indicated for Category A overstates their role, since Category A guidance centers on as-needed short-acting bronchodilators with minimal maintenance therapy.